Selective targeting of IRF4 by synthetic microRNA-125b-5p mimics induces anti-multiple myeloma activity in vitro and in vivo
暂无分享,去创建一个
K. Anderson | N. Munshi | P. Tassone | P. Tagliaferri | A. Neri | M. D. Di Martino | E. Morelli | E. Leone | M. E. G. Cantafio | N. Amodio | L. Biamonte | A. Gullà | U. Foresta | M. Pitari | C. Botta | M. Rossi | P. Tagliaferri | P. Tassone | K. Anderson | M. T. Di Martino | Nikhil C. Munshi | K. C. Anderson | M. T. D. Martino | Annamaria Gullà | Umberto Foresta | Lavinia Biamonte | Emanuela Leone
[1] C. Croce,et al. Downregulation of p53-inducible microRNAs 192, 194, and 215 Impairs the p53/MDM2 Autoregulatory Loop in Multiple Myeloma Development. , 2022, Cancer cell.
[2] P. Tassone,et al. A p53‐Dependent Tumor Suppressor Network Is Induced by Selective miR‐125a‐5p Inhibition in Multiple Myeloma Cells , 2014, Journal of cellular physiology.
[3] P. Tassone,et al. Mir-34: A New Weapon Against Cancer? , 2014, Molecular therapy. Nucleic acids.
[4] Jocelyn T. Kim,et al. Dual mechanisms by which miR-125b represses IRF4 to induce myeloid and B-cell leukemias. , 2014, Blood.
[5] P. Tassone,et al. MicroRNA and multiple myeloma: from laboratory findings to translational therapeutic approaches. , 2014, Current pharmaceutical biotechnology.
[6] T. Chevassut,et al. The Genetic Architecture of Multiple Myeloma , 2014, Advances in hematology.
[7] W. Kuo,et al. miR-30-5p functions as a tumor suppressor and novel therapeutic tool by targeting the oncogenic Wnt/β-catenin/BCL9 pathway. , 2014, Cancer research.
[8] P. Tassone,et al. Targeting of multiple myeloma-related angiogenesis by miR-199a-5p mimics: in vitro and in vivo anti-tumor activity , 2014, Oncotarget.
[9] M. Cannataro,et al. In Vivo Activity of MiR-34a Mimics Delivered by Stable Nucleic Acid Lipid Particles (SNALPs) against Multiple Myeloma , 2014, PloS one.
[10] P. Tassone,et al. In Vitro and In Vivo Activity of a Novel Locked Nucleic Acid (LNA)-Inhibitor-miR-221 against Multiple Myeloma Cells , 2014, PloS one.
[11] P. Tassone,et al. Transferrin-Conjugated SNALPs Encapsulating 2′-O-Methylated miR-34a for the Treatment of Multiple Myeloma , 2014, BioMed research international.
[12] M. Komada,et al. ERK-Dependent Downregulation of Skp2 Reduces Myc Activity with HGF, Leading to Inhibition of Cell Proliferation through a Decrease in Id1 Expression , 2013, Molecular Cancer Research.
[13] P. Tassone,et al. miR-29b induces SOCS-1 expression by promoter demethylation and negatively regulates migration of multiple myeloma and endothelial cells , 2013, Cell cycle.
[14] P. Tassone,et al. miR‐29b negatively regulates human osteoclastic cell differentiation and function: Implications for the treatment of multiple myeloma‐related bone disease , 2013, Journal of cellular physiology.
[15] B. Li,et al. MicroRNA-125b promotes apoptosis by regulating the expression of Mcl-1, Bcl-w and IL-6R , 2013, Oncogene.
[16] D. MacEwan,et al. Attenuation of dexamethasone-induced cell death in multiple myeloma is mediated by miR-125b expression , 2013, Cell cycle.
[17] P. Tassone,et al. Non-coding RNA: a novel opportunity for the personalized treatment of multiple myeloma , 2013, Expert opinion on biological therapy.
[18] Mario Boccadoro,et al. Biological and Clinical Relevance of miRNA Expression Signatures in Primary Plasma Cell Leukemia , 2013, Clinical Cancer Research.
[19] L. Staudt,et al. Control of autophagic cell death by caspase-10 in multiple myeloma. , 2013, Cancer cell.
[20] T. Paíno,et al. Restoration of microRNA-214 expression reduces growth of myeloma cells through positive regulation of P53 and inhibition of DNA replication , 2013, Haematologica.
[21] N. Munshi,et al. Targeting miR-21 Inhibits In Vitro and In Vivo Multiple Myeloma Cell Growth , 2013, Clinical Cancer Research.
[22] M. Cannataro,et al. In Vitro and in Vivo Anti-tumor Activity of miR-221/222 Inhibitors in Multiple Myeloma , 2013, Oncotarget.
[23] Yumeng Sun,et al. Diverse functions of miR-125 family in different cell contexts , 2013, Journal of Hematology & Oncology.
[24] N. Munshi,et al. miR-29b sensitizes multiple myeloma cells to bortezomib-induced apoptosis through the activation of a feedback loop with the transcription factor Sp1 , 2012, Cell Death and Disease.
[25] M. Negrini,et al. Synthetic miR-34a Mimics as a Novel Therapeutic Agent for Multiple Myeloma: In Vitro and In Vivo Evidence , 2012, Clinical Cancer Research.
[26] P. L. Bergsagel,et al. Molecular pathogenesis of multiple myeloma and its premalignant precursor. , 2012, The Journal of clinical investigation.
[27] M. Negrini,et al. DNA-demethylating and anti-tumor activity of synthetic miR-29b mimics in multiple myeloma , 2012, Oncotarget.
[28] A. Waage,et al. Addiction to c-MYC in multiple myeloma. , 2012, Blood.
[29] A. Borkhardt,et al. MiR-125 in normal and malignant hematopoiesis , 2012, Leukemia.
[30] P. Tassone,et al. Molecular targets for the treatment of multiple myeloma. , 2012, Current cancer drug targets.
[31] P. Tassone,et al. Promises and Challenges of MicroRNA-based Treatment of Multiple Myeloma , 2012, Current cancer drug targets.
[32] A. Bader. miR-34 – a microRNA replacement therapy is headed to the clinic , 2012, Front. Gene..
[33] Ryan M. O’Connell,et al. MicroRNA-125b Potentiates Macrophage Activation , 2011, The Journal of Immunology.
[34] R. Young,et al. BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc , 2011, Cell.
[35] I. Jurisica,et al. NAViGaTing the Micronome – Using Multiple MicroRNA Prediction Databases to Identify Signalling Pathway-Associated MicroRNAs , 2011, PloS one.
[36] R. Carrasco,et al. Pathogenesis of myeloma. , 2011, Annual review of pathology.
[37] N. Munshi,et al. A unique three-dimensional SCID-polymeric scaffold (SCID-synth-hu) model for in vivo expansion of human primary multiple myeloma cells , 2011, Leukemia.
[38] J. Gera,et al. IL-6-induced Enhancement of c-Myc Translation in Multiple Myeloma Cells , 2010, The Journal of Biological Chemistry.
[39] Huey-Jen Lin,et al. Downregulation of p53-inducible microRNAs 192, 194, and 215 impairs the p53/MDM2 autoregulatory loop in multiple myeloma development. , 2010, Cancer cell.
[40] C. Croce,et al. Targeting microRNAs in cancer: rationale, strategies and challenges , 2010, Nature Reviews Drug Discovery.
[41] Yong Li,et al. Negative Regulation of the Tumor Suppressor p53 Gene by MicroRNAs , 2010, Oncogene.
[42] Sabyasachi Das,et al. MicroRNA 125b inhibition of B cell differentiation in germinal centers. , 2010, International immunology.
[43] L. Staudt,et al. IRF4: Immunity. Malignancy! Therapy? , 2009, Clinical Cancer Research.
[44] F. Slack,et al. MicroRNAs as potential cancer therapeutics , 2008, Oncogene.
[45] E. Knudsen,et al. Stress and IGF-I Differentially Control Cell Fate through Mammalian Target of Rapamycin (mTOR) and Retinoblastoma Protein (pRB)* , 2008, Journal of Biological Chemistry.
[46] C. Croce,et al. MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis , 2008, Proceedings of the National Academy of Sciences.
[47] L. Staudt,et al. IRF4 addiction in multiple myeloma , 2008, Nature.
[48] Kuo-I Lin,et al. Induction of apoptosis in plasma cells by B lymphocyte-induced maturation protein-1 knockdown. , 2007, Cancer research.
[49] D. Bartel. MicroRNAs Genomics, Biogenesis, Mechanism, and Function , 2004, Cell.
[50] A I Pick,et al. THE TREATMENT OF MULTIPLE MYELOMA , 1948, Harefuah.
[51] D. Chauhan,et al. Bone marrow microenvironment and the identification of new targets for myeloma therapy , 2009, Leukemia.
[52] Tsung-Cheng Chang,et al. Widespread microRNA repression by Myc contributes to tumorigenesis , 2008, Nature Genetics.